Ultragenyx Pharmaceutical (RARE) Competitors $27.30 -0.71 (-2.53%) Closing price 04:00 PM EasternExtended Trading$27.30 0.00 (0.00%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. VRNA, BBIO, BPMC, ROIV, LEGN, ELAN, RGC, RVMD, GRFS, and TGTXShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Legend Biotech Elanco Animal Health Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Which has preferable earnings and valuation, VRNA or RARE? Verona Pharma PLC American Depositary Share has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$42.28M211.42-$173.42M-$2.00-52.50Ultragenyx Pharmaceutical$560.23M4.61-$569.18M-$5.88-4.64 Does the media refer more to VRNA or RARE? In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 14 mentions for Ultragenyx Pharmaceutical and 12 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.73 beat Ultragenyx Pharmaceutical's score of -0.33 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer VRNA or RARE? Verona Pharma PLC American Depositary Share currently has a consensus price target of $109.00, indicating a potential upside of 3.81%. Ultragenyx Pharmaceutical has a consensus price target of $83.64, indicating a potential upside of 206.38%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more risk and volatility, VRNA or RARE? Verona Pharma PLC American Depositary Share has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Do insiders and institutionals have more ownership in VRNA or RARE? 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is VRNA or RARE more profitable? Verona Pharma PLC American Depositary Share has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Verona Pharma PLC American Depositary Share's return on equity of -69.65% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary ShareN/A -69.65% -28.00% Ultragenyx Pharmaceutical -93.04%-186.49%-36.81% SummaryUltragenyx Pharmaceutical beats Verona Pharma PLC American Depositary Share on 9 of the 16 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.65B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-4.6420.7327.9019.95Price / Sales4.61321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book9.898.308.635.90Net Income-$569.18M-$55.19M$3.24B$258.42M7 Day Performance-0.40%5.07%3.22%1.94%1 Month Performance-26.53%17.61%10.72%12.02%1 Year Performance-39.48%7.03%34.94%20.81% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.3469 of 5 stars$27.30-2.5%$83.64+206.4%-38.0%$2.65B$560.23M-4.641,294Upcoming EarningsVRNAVerona Pharma PLC American Depositary Share2.7693 of 5 stars$104.90flat$109.00+3.9%+366.9%$8.93B$42.28M-52.4530BBIOBridgeBio Pharma4.6041 of 5 stars$45.90-1.3%$61.50+34.0%+68.0%$8.72B$221.90M-13.00400Analyst ForecastBPMCBlueprint Medicines1.1533 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsROIVRoivant Sciences2.7048 of 5 stars$11.48+0.3%$16.50+43.7%+3.5%$7.80B$29.05M-45.92860News CoverageInsider TradeLEGNLegend Biotech3.6979 of 5 stars$42.23+1.5%$73.33+73.7%-26.0%$7.76B$627.24M-71.582,609Positive NewsAnalyst RevisionELANElanco Animal Health3.5435 of 5 stars$14.67-0.8%$16.00+9.1%+13.2%$7.28B$4.44B19.829,000Analyst ForecastAnalyst RevisionRGCRegencell Bioscience0.358 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Gap DownRVMDRevolution Medicines4.5858 of 5 stars$38.42+0.3%$68.91+79.4%-19.8%$7.16B$11.58M-9.61250Positive NewsGRFSGrifols3.7973 of 5 stars$10.00+0.6%$10.30+3.0%+27.1%$6.88B$7.81B8.5523,822Upcoming EarningsTGTXTG Therapeutics3.7211 of 5 stars$37.42-1.3%$43.80+17.0%+85.5%$5.94B$329M155.92290Positive News Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Regencell Bioscience Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts